SCHEMBL884690

SCHEMBL884690

Cc1cc(F)ccc1-c1ncccc1CC(c1cccnc1)c1cccnc1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 19/20 0.59
KCNH2 Q12809 9/20 0.51
GRM5 P41594 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2062680 0.84 KCNA5 (0.60) KCNA5KCNH2GRM5
SCHEMBL884939 0.80 KCNA5 (0.64) KCNA5KCNH2
SCHEMBL884407 0.79 KCNA5 (0.73) KCNA5KCNH2
SCHEMBL884594 0.77 KCNA5 (0.69) KCNA5KCNH2
SCHEMBL884815 0.76 KCNA5 (0.68) KCNA5KCNH2
SCHEMBL884508 0.75 KCNA5 (0.64) KCNA5KCNH2
SCHEMBL885216 0.75 KCNA5 (0.74) KCNA5KCNH2
SCHEMBL884763 0.74 KCNA5 (0.69) KCNA5KCNH2
SCHEMBL884728 0.74 KCNA5 (0.74) KCNA5KCNH2
SCHEMBL885826 0.74 KCNA5 (0.74) KCNA5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885GRM5 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.